RUNX1 and acute myeloid leukemia: In the allo-HSCT group, FLT3-ITD and mutations in TP53 and RUNX1 all independently contributed to poor survival, which were consistent with previous research results that FLT3-ITD was associated with increased risk of relapse in AML, RUNX1 mutations were independent predictor for inferior survival and TP53 mutations adversely affect outcome in AML [8–10].